


Product Data Sheet

Otamixaban

| | |
|------------------|---|
| Cat. No.: | A3690 |
| CAS No.: | 193153-04-7 |
| Formula: | C ₂₅ H ₂₆ N ₄ O ₄ |
| M.Wt: | 446.53 |
| Synonyms: | FXV 673; FXV-673; FXV673 |
| Target: | Proteases |
| Pathway: | Thrombin |
| Storage: | Store at -20°C |



Solvent & Solubility

≥22.35 mg/mL in DMSO; insoluble in H₂O; ≥55 mg/mL in EtOH with gentle warming

In Vitro

| Preparing Stock Solutions | Mass | | 1mg | 5mg | 10mg |
|---------------------------|---------|---------------|-----------|------------|------------|
| | Solvent | Concentration | | | |
| | | 1 mM | 2.2395 mL | 11.1975 mL | 22.3949 mL |
| | | 5 mM | 0.4479 mL | 2.2395 mL | 4.4790 mL |
| | | 10 mM | 0.2239 mL | 1.1197 mL | 2.2395 mL |

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Direct factor Xa inhibitors, potent and selective

IC₅₀ & Target

0.5 nM (K_i) (Factor Xa)

In Vitro

Cell Viability Assay

Preparation method:

The solubility of this compound in DMSO is >22.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting conditions:

100 ng/mL

Applications:

The anticoagulant effect of Otamixaban in plasma was

| | | |
|---------|--------------------------|--|
| | | rabbit>human>monkey>rat>dog. Humans were approximately 2.5 fold more sensitive to otamixaban than dogs in both the PT and aPTT assays. 100 ng/mL would be the effective plasma concentration to target for human clinical studies. |
| In Vivo | Animal experiment | |
| | Animal models: | rat model of ferrous chloride-induced arterial thrombosis |
| | Dosage form: | 50 µg/kg bolus and 5 µg/kg/min i.v. maintenance infusion |
| | Applications: | In rat model of ferrous chloride-induced arterial thrombosis, Otamixaban exhibited a dose-dependent increase in time to occlusion with a maximal effective dose at about 50 µg/kg bolus and 5 µg/kg/min i.v. maintenance infusion. Compared to control, this dose caused a 40% reduction in thrombus mass. |
| | Other notes: | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Guertin KR1, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. *Curr Med Chem.* 2007;14(23):2471-81.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

